Advertisement

Eravacycline, a newly approved fluorocycline

  • Young Ran LeeEmail author
  • Caitlin Elizabeth Burton
Review
  • 81 Downloads

Abstract

Complicated intra-abdominal infections (cIAIs) are commonly associated with multimicroorganisms and treatment choices are becoming narrower due to developing resistance, especially in the gram-negative Enterobacteriaceae species. Eravacycline is a newly developed, fully synthetic tetracycline derivative that has shown potent broad-spectrum activity against a wide variety of microorganisms, including those such as extended spectrum β-lactamase producing Enterobacteriaceae and Acinetobacter. Eravacycline has shown activity against many gram-positive organisms such as methicillin-resistant S. aureus and vancomycin resistant Enterococcus faecalis and Enterococcus faecium (VRE), gram-negative organisms such as Escherichia coli, and anaerobic species of microorganisms such as Bacteroides. This fluorocycline has been compared to ertapenem and meropenem for the treatment of complicated intra-abdominal infections and levofloxacin for the treatment of complicated urinary tract infections. Eravacycline was shown to be noninferior to ertapenem but did not meet noninferiority criteria in comparison to levofloxacin. Oral and IV formulations on eravacycline were tested in clinical trials, but at this time, only the IV formulation is FDA approved. Eravacycline has been noted to have a half-life of 20 h with protein binding around 80%; AUC over minimum inhibitory concentration (MIC) has also been shown to be eravacycline’s best predictor of efficacy. Of note, eravacycline does not require any renal dose adjustments, as the majority of its clearance is by nonrenal pathways.

Keywords

Eravacycline Fluorocycline Intra-abdominal infections Drug resistance 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, Pascual A. (2018) Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae. Clin Microbiol Rev 31(2)Google Scholar
  2. 2.
    Antibiotic/Antimicrobial Resistance. Centers for Disease Control and Prevention website. https://www.cdc.gov/drugresistance/index.html. Last reviewed August 18, 2017. Last Updated March 29, 2018. Accessed 6 Sept 2018
  3. 3.
    Antimicrobial Drug Resistance. World Health Organization website. http://www.who.int/csr/disease/OP_AMR_FINAL.pdf. Accessed 6 Sept 2018
  4. 4.
    Global action plan on antimicrobial resistance. World Health Organization website. http://www.who.int/antimicrobial-resistance/global-action-plan/en/. Accessed 6 Sept 2018
  5. 5.
    Generating antibiotic incentives now. Food and Drug Administration website. https://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/UCM595188.pdf. Accessed 6 Sept 2018
  6. 6.
    FDA awards fast track status to tetraphase pharmaceuticals for IV and oral formulations of eravacycline [news release]. Tetraphase Pharmaceuticals, Watertown, MA. April 2, 2014. https://ir.tphase.com/news-releases/news-release-details/fda-awards-fast-track-status-tetraphase-pharmaceuticals-iv-and#. Accessed 6 Sept 2018
  7. 7.
    Solomkin J, Evans D, Slepavicius A et al (2017) Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial. JAMA Surg 152(3):224–232CrossRefGoogle Scholar
  8. 8.
    Xiao XY, Hunt DK, Zhou J et al (2012) Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent. J Med Chem 55(2):597–605CrossRefGoogle Scholar
  9. 9.
    Sutcliffe JA, O’Brien W, Fyfe C, Grossman TH (2013) Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother 57(11):5548–5558CrossRefGoogle Scholar
  10. 10.
    CLSI (2016) Performance Standards for Antimicrobial Susceptibility Testing, 26th edn. CLSI Supplement M100S. Clinical and Laboratory Standards Institute, WayneGoogle Scholar
  11. 11.
    Goldstein EC, Citron DM, Tyrrell KL (2018) In vitro activity of eravacycline and comparator antimicrobials against 143 recent strains of Bacteroides and Parabacteroides species. Anaerobe 52:122–124CrossRefGoogle Scholar
  12. 12.
    Mandell LA, Wunderink RG, Anzueto A et al (2007) Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44(suppl 2):S27–S72CrossRefGoogle Scholar
  13. 13.
    Zhanel GG, Cheung D, Adam H et al (2016) Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs 76:567–588CrossRefGoogle Scholar
  14. 14.
    Dubois J, Dubois M, Martel JF, Grossman T, Sutcliffe J (2010) In vitro activity of fluorocyclines against Legionella pneumophila, poster 178. 50th ICAAC, BostonGoogle Scholar
  15. 15.
    Thabit AK, Monogue ML, Nicolau DP (2016) Eravacycline pharmacokinetics and challenges in defining humanized exposure in vivo. Antimicrob Agents Chemother 60(8):5072–5075CrossRefGoogle Scholar
  16. 16.
    Connors KP, Housman ST, Pope JS et al (2014) Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women. Antimicrob Agents Chemother 58(4):2113–2118CrossRefGoogle Scholar
  17. 17.
    Leighton A, Zupanets I, Bezugla N, Plamondon L, Macdonald G, Sutcliffe J (2011) Broad spectrum fluorocycline TP-434 has oral bioavailability in humans, poster 1509. 21st ECCMID/27th ICC, Milan, ItalyGoogle Scholar
  18. 18.
    Newman JV, Zhou J, Izmailyan S, Tsai L (2018) Randomized, double-blind, placebo-controlled studies of the safety and pharmacokinetics of single and multiple ascending doses of eravacycline. Antimicrob Agents Chemother 62(11):e01174–e01118CrossRefGoogle Scholar
  19. 19.
    Thabit AK, Monogue ML, Newman JV, Nicolau DP (2018) Assessment of in vivo efficacy of eravacycline against Enterobacteriaceae exhibiting various resistance mechanisms: a dose-ranging study and pharmacokinetic/pharmacodynamic analysis. Int J Antimicrob Agents 51(5):727–732CrossRefGoogle Scholar
  20. 20.
    Eravacycline (2018) Package insert. Tetraphase Pharmaceuticals, WatertownGoogle Scholar
  21. 21.
    Grossman TH, O’Brien W, Kerstein KO, Sutcliffe JA (2015) Eravacycline (TP-434) is active in vitro against biofilms formed by uropathogenic Escherichia coli. Antimicrob Agents Chemother 59(4):2446–2449CrossRefGoogle Scholar
  22. 22.
    Monogue ML, Thabit AK, Hamada Y, Nicolau DP (2016) Antibacterial efficacy of eravacycline in vivo against gram-positive and gram-negative organisms. Antimicrob Agents Chemother 60(8):5001–5005CrossRefGoogle Scholar
  23. 23.
    Rodvold KA, Danziger LH, Gotfried MH (2003) Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. Antimicrob Agents Chemother 47(8):2450–2457CrossRefGoogle Scholar
  24. 24.
    Solomkin JS, Ramesh MK, Cesnauskas G et al (2014) Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections. Antimicrob Agents Chemother 58(4):1847–1854CrossRefGoogle Scholar
  25. 25.
    Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E (2005) The efficacy and safety of tigecycline for the treatment of complicated intraabdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 41(Suppl 5):S354–S367CrossRefGoogle Scholar
  26. 26.
    Honore PM, Spapen HD (2017) Eravacycline for treatment of complicated intra-abdominal infections: the fire is not ignited! Ann Transl Med 5(21):425CrossRefGoogle Scholar
  27. 27.
    Solomkin JS, Gardovskis J, Lawrence K et al (2018) IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs. meropenem in the treatment of complicated intra-abdominal infections. Clin Infect DisGoogle Scholar
  28. 28.
    Tetraphase announces top-line results from IGNITE2 phase 3 clinical trial of eravacycline in cUTI [news release]. Tetraphase Pharmaceuticals, Watertown, MA. September 8, 2015. http://ir.tphase.com/news-releases/news-release-details/tetraphase-announces-top-line-results-ignite2-phase-3-clinical. Accessed 7 March 2019
  29. 29.
    Tetraphase announces top-line results from IGNITE3 phase 3 clinical trial of eravacycline in complicated urinary tract infections (cUTI). Tetraphase Pharmaceuticals, Watertown, MA. February 13, 2018. http://ir.tphase.com/news-releases/news-release-details/tetraphase-announces-top-line-results-ignite3-phase-3-clinical. Accessed 6 Aug 2018

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Pharmacy PracticeTexas Tech University Health Sciences Center School of PharmacyAbileneUSA
  2. 2.Texas Tech University Health Sciences Center School of PharmacyAbileneUSA

Personalised recommendations